Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheli Melzer Cohen

Showing results (31-40 of 32) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 32 results.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
JAMA|October 3, 2023
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis, Morgan E Grams, Josef Coresh, et al.
Pageof 4

Showing results (31-40 of 32) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 32 results.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
JAMA|October 3, 2023
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis, Morgan E Grams, Josef Coresh, et al.
Pageof 4